Press Releases

-- Vertex to receive $105 million from Mitsubishi following signing, plus the potential for additional milestones upon commercialization ---- Phase 3 registration program for telaprevir in Japan expected to complete enrollment in the third quarter of 2009 --

CAMBRIDGE, Mass., Jul 27, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2009 financial results on Wednesday, August 5, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.

- Vertex holds rights to earn up to $250 million in milestones associated with filing, approval and launch of telaprevir in Europe -

CAMBRIDGE, Mass., Jul 07, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Jeffrey Leiden, M.D., Ph.D. and Dennis Winger joined its board of directors. "Jeff and Dennis add tremendous medical and biomedical business perspective to our board.

CAMBRIDGE, Mass., Jun 23, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2009 Piper Jaffray Europe Conference on Tuesday, June 23, 2009 at 4:30 p.m. BST (11:30 a.m. EDT).

CAMBRIDGE, Mass., Jun 08, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $103.3 million in aggregate principal amount of those notes for

-- Together with agreements announced earlier today, a total of $143.5 million in convertible notes to be exchanged--

CAMBRIDGE, Mass., Jun 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Goldman Sachs 30 th Annual Global Healthcare Conference. Matt Emmens, Chairman, President and Chief Executive Officer of Vertex, will

-Registration program to evaluate improvements in lung function (FEV₁), restoration of CFTR activity and safety--Program designed to support registration in cystic fibrosis patients with the G551D mutation and to provide first evaluation of activity in patients with F508del mutations--Primary endpoint for patients with G551D mutation is improvement in FEV₁ through 24 weeks-

-Over 3 million Americans have chronic hepatitis C - -Baby boomers account for 2 of every 3 cases of hepatitis C virus and vast majority unaware they have this chronic disease - -Cost burden of hepatitis C to Medicare projected to increase 500% as baby boomers with HCV age into severe complications of liver disease-

CAMBRIDGE, Mass., May 14, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2009 Annual Meeting of Stockholders. At the meeting, stockholders approved the amendment to Vertex's Amended and Restated 2006 Stock and Option Plan

CAMBRIDGE, Mass., May 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Bank of America and Merrill Lynch 2009 Health Care Conference on Tuesday, May 12, 2009 at 8:40 a.m. EDT; at R. W.

CAMBRIDGE, Mass., May 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Dr. Peter Mueller, Vertex's Executive Vice President, Drug Innovation and Realization and Chief Scientific Officer, will expand his leadership responsibilities to cover all of

-Addition of telaprevir to standard HCV therapies significantly improved rates of sustained viral response in half the time of current treatments--SVR rates in Phase 2b studies of up to 69% with 24 weeks of telaprevir-based treatment--Phase 3 program ongoing in more than 2,200 patients-

- Superior SVR rates with telaprevir across all HCV genotype 1 non-responders and relapser patients and patients with cirrhosis - up to 76% in prior relapsers -- PROVE 3 showed 51% and 52% SVR rates in telaprevir-based regimens compared to 14% in the 48-week control arm-- Treatment-failure patient population represents the greatest unmet medical need in HCV -

-PROVE 3 results to be presented at late breaker session on Saturday, April 25, 2009--Interim data from two Phase 2 studies of telaprevir indicate activity across multiple genotypes in treatment-naïve HCV patients--Early data from newly-acquired polymerase inhibitors suggest rapid, powerful antiviral activity with favorable safety and tolerability profile-

- Telaprevir registration program on track; VCH-222 enters multi-dose, 3-day viral kinetic study -- VX-770 will start registration program in CF patients with G551D mutation --Vertex ends first quarter with $869 million of cash, cash equivalents and marketable securities-

CAMBRIDGE, Mass., Apr 03, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2009 financial results on Thursday, April 16, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.

CAMBRIDGE, Mass., Mar 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at Citi's 4 th Annual Biotech Day on Wednesday, April 1, 2009 at 2:40 p.m. EDT and at the Canaccord Adams Hepatitis C Conference on

- Primary endpoints of safety and tolerability to be evaluated in Phase 2a clinical trial -- Measurements of CFTR function to be assessed as secondary endpoints -- Trial to enroll approximately 90 patients with the F508del CFTR mutation -